Key result
Percutaneous coronary intervention for in-stent restenotic chronic total occlusion was associated with higher 30-day all-cause mortality (P=0.05) and 5-year MI (P=0.07) than de-novo CTO PCI.
Why the study?
Few studies have reported the short- and long-term clinical outcomes and procedure success rate of in-stent restenotic chronic total occlusion (ISR-CTO) PCI.
Does percutaneous coronary intervention for in-stent restenotic chronic total occlusion improve clinical outcomes compared to de-novo chronic total occlusion in patients undergoing PCI?
Cohort (n=2,659)
No
Does percutaneous coronary intervention for in-stent restenotic chronic total occlusion improve clinical outcomes compared to de-novo chronic total occlusion in patients undergoing PCI?
PCI for in-stent restenotic CTO is associated with higher rates of suboptimal recanalization and worse short-term mortality compared to de-novo CTO PCI.
ISR-CTO PCI was associated with higher short-term mortality and long-term MI risk than de-novo CTO PCI; leaves open whether procedural optimization improves outcomes.
OBJECTIVES: To investigate the procedure success rate and clinical outcomes of in-stent restenotic chronic total occlusion (ISR-CTO) percutaneous coronary intervention (PCI). BACKGROUND: Few studies have reported the short- and long-term clinical outcomes of ISR-CTO PCI. METHOD: Patients who underwent ISR-CTO (n = 212) or de-novo CTO (n = 2,447) PCI at Fuwai Hospital from 2010 to 2013 were enrolled. Thirty-day and 5-year clinical outcomes were analyzed. The primary outcome was the incidence of all-cause death, myocardial infarction (MI), and heart failure at follow-up. The secondary outcome was the recanalization result (reasonable, suboptimal, or failed recanalization). RESULTS: ISR-CTO PCI had a higher rate of suboptimal recanalization than de-novo CTO PCI (p < .01). The syntax score before PCI (odds ratio (OR): 1.06; 95% confidence interval (CI): 1.02-1.10; p = .002) and occlusion length ≥ 20 mm (OR: 2.70:95% CI: 1.46-4.98; p = .001) were predictors of suboptimal recanalization in ISR-CTO PCI. Cardiac death (p = .03) and 30-day all-cause mortality (p = .05) were higher among patients who underwent ISR-CTO PCI. The ISR-CTO group had a higher rate of MI (p = .07) at 5 years. Suboptimal recanalization (hazard ratio: 2.56; 95% CI: 1.13-5.83; p = .025) was an independent predictor of long-term major adverse events in ISR-CTO. CONCLUSIONS: Suboptimal recanalization, 30-day cardiac death, and long-term MI rates are higher for ISR-CTO PCI than de-novo CTO PCI. Suboptimal recanalization is an independent predictor of long-term major adverse events after ISR-CTO PCI.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a cohort in In-stent restenotic chronic total occlusion (ISR-CTO) (n=2,659). Percutaneous coronary intervention for in-stent restenotic chronic total occlusion vs. Percutaneous coronary intervention for de-novo chronic total occlusion was evaluated on Incidence of all-cause death, myocardial infarction (MI), and heart failure at follow-up. Percutaneous coronary intervention for in-stent restenotic chronic total occlusion was associated with higher 30-day all-cause mortality (P=0.05) and 5-year MI (P=0.07) than de-novo CTO PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: